BioCentury
ARTICLE | Financial News

MRL, Baupost lead RaNA's $55M B round

July 24, 2015 1:13 AM UTC

RaNA Therapeutics Inc. (Cambridge, Mass.) raised $55 million in an oversubscribed series B round co-led by MRL Ventures, the venture arm of Merck & Co. Inc. (NYSE:MRK), and The Baupost Group. New investors Rock Springs Capital; Brookside Capital; and Leerink Partners also participated, along with existing investors Atlas Venture; Monsanto; MS Ventures; Omega Funds; Partners Innovation Fund; Pfizer Venture Investments; and SR One.

RaNA develops synthetic oligonucleotides that can selectively stabilize mRNA or regulate epigenetic activity to increase protein abundance. CEO Ronald Renaud told BioCentury that the oligonucleotides have potential in diseases caused by haploinsufficiency. ...